OPKO HEALTH, INC. business relationships
Companies named in OPKO HEALTH, INC.’s 10-K filed 2026-02-26, and public companies whose annual reports name OPKO HEALTH, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 92 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Layers: PeptidesGLP-1 & obesity
Named in OPKO HEALTH, INC.’s annual report 15
“In addition to the CTP patents and applications licensed to Pfizer, OPKO has multiple patent families covering similar biologicals with patents and applications pending in the U.S. and internationally.” SEC filing
“...Sanofi of $12.5 million made in 2023 pursuant to the Sanofi In-License Agreement, which was triggered as a result of the Merck Agreement, and lower costs related to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has received marketing authorization.” SEC filing
“Amended and Restated Development and Commercialization License Agreement by and between Pfizer Inc. and OPKO Ireland Ltd., dated May 12, 2020, filed with the Company's Quarterly Report on Form 10⁃Q filed with the Securities and Exchange Commission on July 31, 2020 for the Company's three-month perio...” SEC filing
“On January 7, 2025, ModeX announced the dosing of the first participant in a Phase 1 study for an EBV vaccine candidate being developed in collaboration with Merck.” SEC filing
“We have partnered with Pfizer Inc. ("Pfizer") for further development and commercialization of Somatrogon (hGH-CTP).” SEC filing
“On October 28, 2025, ModeX entered into a license and collaboration agreement (the "Regeneron Collaboration Agreement") with Regeneron Pharmaceuticals Inc. ("Regeneron") to discover and develop multispecific antibodies for several therapeutic indications of mutual interest.” SEC filing
“Certain of the rights subject to the license provided by us under the Merck Agreement were obtained by us from Sanofi pursuant to that certain License Agreement entered into as of July 1, 2021 ("Sanofi In-License Agreement") between us and Sanofi, a French corporation ("Sanofi"), and a portion of th...” SEC filing
“We are substantially dependent on Pfizer for the successful commercialization of such product.” SEC filing
“...d of gross profit share and royalty payments for NGENLA ® and Pfizer's Genotropin, a $ 7.0 million upfront payment from Regeneron, $ 4.3 million in royalty revenue from Eli Lilly following the commercial launch of Mazdutide in China and $ 7.4 million from contract manufacturers' commercial milestone...” SEC filing
“ModeX and Sanofi are parties to the Sanofi In-License Agreement, pursuant to which ModeX licenses certain intellectual property underlying its Epstein-Barr Virus (EBV) technology.” SEC filing
“Additionally, we maintain a license agreement with Eli Lilly and Company ("Eli Lilly"), under which we receive royalty payments for certain licensed intellectual property.” SEC filing
“...of gross profit share and royalty payments for NGENLA ® and Pfizer's Genotropin, a $ 7.0 million upfront payment from Regeneron, $ 4.3 million in royalty revenue from Eli Lilly following the commercial launch of Mazdutide in China and $ 7.4 million from contract manufacturers' commercial milestones.” SEC filing
“Exclusive License Agreement, dated July 6, 2021, by and between OPKO Health, Inc. and CAMP4 Therapeutics Corporation, filed with the Company's Quarterly Report on Form 10⁃Q filed with the Securities and Exchange Commission on July 29, 2021 for the Company's three-month period ended June 30, 2021, an...” SEC filing
“OPK-88006 (Oral): In collaboration with Entera Bio Ltd. ("Entera"), we are advancing a once-daily tablet formulation of OPK-88006.” SEC filing
“Amendment to Development and License Agreement between EirGen Pharma Ltd. and Vifor Fresenius Medical Care Renal Pharma Ltd., dated May 5, 2020, filed with the Company's Quarterly Report on Form 10⁃Q filed with the Securities and Exchange Commission on July 31, 2020 for the Company's three-month per...” SEC filing
Companies whose annual reports name OPKO HEALTH, INC. 6
“(15) Ngenla is licensed from OPKO Health, Inc., and is developed and commercialized by Pfizer, including in the U.S., Latin America, Europe, Africa, and Asia.” SEC filing
“VFMCRP has an exclusive license agreement with OPKO Health, Inc., to co-develop and commercialize Rayaldee ® in Europe (except Russia), Canada, Australia and Japan.” SEC filing
“Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD.” SEC filing
“| Distribution Agreement, dated as of October 12, 2023, by and between OPKO Health Spain, S.L.U. and NextPlat Corp (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 18, 2023) . |” SEC filing
“Amended and Restated Collaboration and License Agreement, dated February 3, 2026, by and among Entera Bio Ltd., OPKO Health, Inc. and OPKO Biologics Ltd. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on February 4, 2026)” SEC filing
“...we announced new in vivo PK/PD data supporting the development of a proprietary long-acting PTH (LA-PTH) analog, which is being developed as part of a material transfer and collaboration agreement with OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. ("OPKO"), utilizing our N-Tab ® platform.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.